JP2008502614A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008502614A5 JP2008502614A5 JP2007515811A JP2007515811A JP2008502614A5 JP 2008502614 A5 JP2008502614 A5 JP 2008502614A5 JP 2007515811 A JP2007515811 A JP 2007515811A JP 2007515811 A JP2007515811 A JP 2007515811A JP 2008502614 A5 JP2008502614 A5 JP 2008502614A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- heteroaryl
- fluorine
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052731 fluorine Inorganic materials 0.000 claims 52
- 239000011737 fluorine Substances 0.000 claims 50
- 125000001424 substituent group Chemical group 0.000 claims 48
- 125000001072 heteroaryl group Chemical group 0.000 claims 44
- 125000000623 heterocyclic group Chemical group 0.000 claims 42
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 37
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 37
- 239000000460 chlorine Substances 0.000 claims 36
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 35
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 35
- 229910052801 chlorine Inorganic materials 0.000 claims 35
- 229910052739 hydrogen Inorganic materials 0.000 claims 30
- 239000001257 hydrogen Substances 0.000 claims 30
- -1 hydroxy, methoxy Chemical group 0.000 claims 26
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 24
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 24
- 229910052794 bromium Inorganic materials 0.000 claims 24
- 125000004093 cyano group Chemical group *C#N 0.000 claims 21
- 125000001153 fluoro group Chemical group F* 0.000 claims 21
- 125000003118 aryl group Chemical group 0.000 claims 20
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 20
- 125000004076 pyridyl group Chemical group 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000002541 furyl group Chemical group 0.000 claims 12
- 125000004043 oxo group Chemical group O=* 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 11
- 229910052757 nitrogen Inorganic materials 0.000 claims 10
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 9
- 125000001544 thienyl group Chemical group 0.000 claims 9
- 239000012634 fragment Substances 0.000 claims 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 125000003386 piperidinyl group Chemical group 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 claims 6
- 125000002883 imidazolyl group Chemical group 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 6
- 125000002757 morpholinyl group Chemical group 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 125000004193 piperazinyl group Chemical group 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 4
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 4
- 125000001041 indolyl group Chemical group 0.000 claims 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 4
- 125000001984 thiazolidinyl group Chemical group 0.000 claims 4
- 125000000335 thiazolyl group Chemical group 0.000 claims 4
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000005048 dihydroisoxazolyl group Chemical group O1N(CC=C1)* 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims 3
- 239000000243 solution Substances 0.000 claims 3
- 239000003826 tablet Substances 0.000 claims 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 3
- 125000001425 triazolyl group Chemical group 0.000 claims 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 238000007675 cardiac surgery Methods 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 239000003638 chemical reducing agent Substances 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 125000005956 isoquinolyl group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 2
- 230000000451 tissue damage Effects 0.000 claims 2
- 231100000827 tissue damage Toxicity 0.000 claims 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- YMMHAIJRFWRDMG-UHFFFAOYSA-N 3,4,4a,5-tetrahydro-1h-quinolin-2-one Chemical group C1C=CC=C2NC(=O)CCC21 YMMHAIJRFWRDMG-UHFFFAOYSA-N 0.000 claims 1
- AMTRUQYJMJGKBL-UHFFFAOYSA-N 3-methyl-4-(3-methylsulfonylanilino)-5,6,7,8-tetrahydro-2h-isoquinolin-1-one Chemical compound CC=1NC(=O)C=2CCCCC=2C=1NC1=CC=CC(S(C)(=O)=O)=C1 AMTRUQYJMJGKBL-UHFFFAOYSA-N 0.000 claims 1
- YQHDPXOKPWZVOC-UHFFFAOYSA-N 3-methyl-4-[5-(pyrrolidin-1-ylmethyl)furan-2-yl]-5,6,7,8-tetrahydro-2h-isoquinolin-1-one Chemical compound CC=1NC(=O)C=2CCCCC=2C=1C(O1)=CC=C1CN1CCCC1 YQHDPXOKPWZVOC-UHFFFAOYSA-N 0.000 claims 1
- YUDTZZNPHBZRAS-UHFFFAOYSA-N 4-(3-acetylanilino)-3-methyl-5,6,7,8-tetrahydro-2h-isoquinolin-1-one Chemical compound CC(=O)C1=CC=CC(NC=2C=3CCCCC=3C(=O)NC=2C)=C1 YUDTZZNPHBZRAS-UHFFFAOYSA-N 0.000 claims 1
- SCRJIIOWXOEMEL-UHFFFAOYSA-N 4-[5-(butylaminomethyl)furan-2-yl]-3-methyl-5,6,7,8-tetrahydro-2h-isoquinolin-1-one Chemical compound O1C(CNCCCC)=CC=C1C1=C(C)NC(=O)C2=C1CCCC2 SCRJIIOWXOEMEL-UHFFFAOYSA-N 0.000 claims 1
- KCBXCZRKDGPVBK-UHFFFAOYSA-N 4-[5-(butylaminomethyl)furan-2-yl]-5,6,7,8-tetrahydro-2h-isoquinolin-1-one Chemical compound O1C(CNCCCC)=CC=C1C1=CNC(=O)C2=C1CCCC2 KCBXCZRKDGPVBK-UHFFFAOYSA-N 0.000 claims 1
- ZORYARKCMSNXMI-UHFFFAOYSA-N 4-[5-(hydroxymethyl)furan-2-yl]-3-methyl-5,6,7,8-tetrahydro-2h-isoquinolin-1-one Chemical compound CC=1NC(=O)C=2CCCCC=2C=1C1=CC=C(CO)O1 ZORYARKCMSNXMI-UHFFFAOYSA-N 0.000 claims 1
- WFYYIOCLGYCULL-UHFFFAOYSA-N 4-[5-[(3-hydroxypyrrolidin-1-yl)methyl]furan-2-yl]-5,6,7,8-tetrahydro-2h-isoquinolin-1-one Chemical compound C1C(O)CCN1CC1=CC=C(C=2C=3CCCCC=3C(=O)NC=2)O1 WFYYIOCLGYCULL-UHFFFAOYSA-N 0.000 claims 1
- IUBOGSIYFVKAKN-UHFFFAOYSA-N 4-[5-[[(1-methylpyrazol-4-yl)methylamino]methyl]furan-2-yl]-5,6,7,8-tetrahydro-2h-isoquinolin-1-one Chemical compound C1=NN(C)C=C1CNCC1=CC=C(C=2C=3CCCCC=3C(=O)NC=2)O1 IUBOGSIYFVKAKN-UHFFFAOYSA-N 0.000 claims 1
- IXNBQNGCXHQJMD-UHFFFAOYSA-N 4-[5-[[(2-hydroxy-2-phenylethyl)amino]methyl]furan-2-yl]-5,6,7,8-tetrahydro-2h-isoquinolin-1-one Chemical compound C=1C=C(C=2C=3CCCCC=3C(=O)NC=2)OC=1CNCC(O)C1=CC=CC=C1 IXNBQNGCXHQJMD-UHFFFAOYSA-N 0.000 claims 1
- QPJZJEZAQVNJIM-UHFFFAOYSA-N 4-[5-[[(4-methylpiperazin-1-yl)methylamino]methyl]furan-2-yl]-5,6,7,8-tetrahydro-2h-isoquinolin-1-one Chemical compound C1CN(C)CCN1CNCC1=CC=C(C=2C=3CCCCC=3C(=O)NC=2)O1 QPJZJEZAQVNJIM-UHFFFAOYSA-N 0.000 claims 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims 1
- 239000005695 Ammonium acetate Substances 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 206010028851 Necrosis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000012661 PARP inhibitor Substances 0.000 claims 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 229940043376 ammonium acetate Drugs 0.000 claims 1
- 235000019257 ammonium acetate Nutrition 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000005418 aryl aryl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000005779 cell damage Effects 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 208000037887 cell injury Diseases 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000003094 microcapsule Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000037891 myocardial injury Diseases 0.000 claims 1
- 239000007922 nasal spray Substances 0.000 claims 1
- 229940097496 nasal spray Drugs 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000006268 reductive amination reaction Methods 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229940098465 tincture Drugs 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004028973.5 | 2004-06-16 | ||
| DE102004028973A DE102004028973A1 (de) | 2004-06-16 | 2004-06-16 | Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| PCT/EP2005/005871 WO2005123687A1 (de) | 2004-06-16 | 2005-06-01 | Substituierte tetrahydro-2h-isochinolin-1-on-derivate, verfahren zu ihrer herstellung und ihre verwendung als medikament |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008502614A JP2008502614A (ja) | 2008-01-31 |
| JP2008502614A5 true JP2008502614A5 (enExample) | 2008-07-10 |
| JP4928446B2 JP4928446B2 (ja) | 2012-05-09 |
Family
ID=35057156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007515811A Expired - Fee Related JP4928446B2 (ja) | 2004-06-16 | 2005-06-01 | 置換されたテトラヒドロ−２ｈ−イソキノリン−１−オン誘導体、その製造方法及び薬剤としてのその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7795278B2 (enExample) |
| EP (1) | EP1758864B1 (enExample) |
| JP (1) | JP4928446B2 (enExample) |
| KR (1) | KR101169919B1 (enExample) |
| CN (1) | CN1968929B (enExample) |
| AU (1) | AU2005254632B2 (enExample) |
| BR (1) | BRPI0512139A (enExample) |
| CA (1) | CA2570942C (enExample) |
| DE (1) | DE102004028973A1 (enExample) |
| IL (1) | IL179758A (enExample) |
| MX (1) | MXPA06013876A (enExample) |
| WO (1) | WO2005123687A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007113202A1 (en) | 2006-03-31 | 2007-10-11 | Glaxo Group Limited | Piperazine derivatives as growth hormone secretagogue (ghs) receptor agonists |
| EP2296653B1 (en) | 2008-06-03 | 2016-01-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
| US8735391B2 (en) * | 2008-09-26 | 2014-05-27 | University Of Kansas | Synthesis of functionalized octahydro-isoquinolin-1-one-8-carboxamides, octahydro-isoquinolin-1-one-8-carboxylic esters and analogs, and therapeutic methods |
| EP2364983B1 (en) * | 2008-11-11 | 2013-10-23 | Jeil Pharmaceutical Co., Ltd. | Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same |
| WO2010081778A1 (en) | 2009-01-17 | 2010-07-22 | Universität Zürich | Blockers of parp for the prevention and treatment of helicobacter pylori induced gastric cancer |
| TWI499418B (zh) * | 2009-05-21 | 2015-09-11 | Nerviano Medical Sciences Srl | 異喹啉－１（２ｈ）－酮衍生物 |
| CN101602725B (zh) * | 2009-07-21 | 2012-07-11 | 浙江大学 | 六氢异喹啉酮类化合物的合成方法 |
| WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
| EP2593434A1 (en) | 2010-07-16 | 2013-05-22 | Purdue Pharma LP | Pyridine compounds as sodium channel blockers |
| US9206127B2 (en) | 2012-03-16 | 2015-12-08 | Purdue Pharm, L.P. | Substituted pyridines as sodium channel blockers |
| AR092742A1 (es) * | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| US9714252B2 (en) | 2012-12-20 | 2017-07-25 | Purdue Pharma L.P. | Cyclic sulfonamides as sodium channel blockers |
| RU2692485C2 (ru) | 2014-04-02 | 2019-06-25 | Интермьюн, Инк. | Противофиброзные пиридиноны |
| US10730866B2 (en) | 2014-04-07 | 2020-08-04 | Purdue Pharma L.P. | Indole derivatives and use thereof |
| CN105272936B (zh) * | 2014-05-27 | 2019-05-17 | 中国科学院上海药物研究所 | 一类氮芳基苯并噻唑类parp抑制剂及其制备方法和用途 |
| CN104163796A (zh) * | 2014-08-04 | 2014-11-26 | 上海师范大学 | 一类取代的1,2,3,4-四氢喹啉-4-酮盐酸盐的制备方法 |
| PH12017502228B1 (en) * | 2015-06-09 | 2022-08-03 | Onconic Therapeutics Inc | Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same |
| AU2016296905B2 (en) | 2015-07-23 | 2018-07-05 | Centre National De La Recherche Scientifique | Use of a combination of Dbait molecule and parp inhibitors to treat cancer |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| EP3615026B1 (en) | 2017-04-28 | 2021-03-03 | Akribes Biomedical GmbH | A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing |
| JP7534218B2 (ja) | 2018-03-13 | 2024-08-14 | ヴァレリオ・セラピューティクス | がんの治療における獲得耐性に対抗するｄｂａｉｔ分子 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN114437072B (zh) * | 2020-10-30 | 2023-03-31 | 中国科学院大连化学物理研究所 | 一种6-甲基异吲哚并[2,1-a]喹喔啉类化合物的合成方法 |
| GB202217888D0 (en) * | 2022-11-29 | 2023-01-11 | Duke Street Bio Ltd | Pharmaceutical compound |
| WO2024261243A1 (en) | 2023-06-21 | 2024-12-26 | Hemispherian As | Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3594380A (en) * | 1969-02-18 | 1971-07-20 | American Home Prod | Isoquinolin-1(2h)-ones |
| EP0355750B1 (en) * | 1988-08-19 | 1995-01-25 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
| US20020022636A1 (en) * | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
| US6444676B1 (en) * | 1999-12-20 | 2002-09-03 | Iok-Hou Pang | Use of PARP inhibitors in the treatment of glaucoma |
| EP1397350B1 (en) * | 2001-05-08 | 2007-02-28 | Kudos Pharmaceuticals Limited | Isoquinolinone derivatives as parp inhibitors |
| JP2004043458A (ja) * | 2002-05-22 | 2004-02-12 | Kyorin Pharmaceut Co Ltd | ４−アリール−５−ヒドロキシイソキノリン誘導体およびその製造法 |
| DE10233388A1 (de) * | 2002-07-23 | 2004-02-12 | Basf Ag | Verfahren zur kontinuierlich betriebenen Reindestillation des bei der koppel-produktfreien Propylenoxidsynthese verwendeten Lösungsmittels Methanol unter gleichzeitiger Abtrennung der Methoxypropanole und der Schwersieder |
| WO2004024694A1 (ja) * | 2002-09-10 | 2004-03-25 | Kyorin Pharmaceutical Co., Ltd. | ４-置換アリール-５-ヒドロキシイソキノリノン誘導体 |
| PE20060285A1 (es) * | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
-
2004
- 2004-06-16 DE DE102004028973A patent/DE102004028973A1/de not_active Withdrawn
-
2005
- 2005-06-01 MX MXPA06013876A patent/MXPA06013876A/es active IP Right Grant
- 2005-06-01 EP EP05754335.7A patent/EP1758864B1/de not_active Expired - Lifetime
- 2005-06-01 JP JP2007515811A patent/JP4928446B2/ja not_active Expired - Fee Related
- 2005-06-01 AU AU2005254632A patent/AU2005254632B2/en not_active Ceased
- 2005-06-01 CN CN2005800201245A patent/CN1968929B/zh not_active Expired - Fee Related
- 2005-06-01 KR KR1020067026566A patent/KR101169919B1/ko not_active Expired - Fee Related
- 2005-06-01 BR BRPI0512139-6A patent/BRPI0512139A/pt not_active IP Right Cessation
- 2005-06-01 CA CA2570942A patent/CA2570942C/en not_active Expired - Fee Related
- 2005-06-01 WO PCT/EP2005/005871 patent/WO2005123687A1/de not_active Ceased
-
2006
- 2006-11-30 IL IL179758A patent/IL179758A/en not_active IP Right Cessation
- 2006-12-06 US US11/567,352 patent/US7795278B2/en not_active Expired - Fee Related
-
2010
- 2010-08-04 US US12/850,328 patent/US20110021462A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008502614A5 (enExample) | ||
| EP3820860B1 (en) | Pyridazine compounds for inhibiting nav1.8 | |
| US12234221B2 (en) | Pyridine carboxamide compounds for inhibiting NAV1.8 | |
| CA2570942A1 (en) | Substituted tetrahydro-2h-isoquinolin-1-one derivatives, method for the production thereof, and use of the same as medicament | |
| JP6409001B2 (ja) | Ｈｂｖ感染に対する新規抗ウイルス剤 | |
| CN105073738B (zh) | 作为钠通道调节剂的喹啉及喹喔啉酰胺类 | |
| TWI313264B (en) | Triamide-substituted heterobicyclic compounds | |
| CA2932010C (en) | Urea derivative or pharmacologically acceptable salt thereof | |
| CA3093851A1 (en) | Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same | |
| US11945796B2 (en) | Substituted pyridine derivatives as SARM1 inhibitors | |
| JP4602672B2 (ja) | プロスタグランジンｆ受容体のモジュレーターとしてのチアゾリジンカルボキサミド誘導体 | |
| TWI659950B (zh) | 作為硝醯基予體之吡唑啉酮衍生物 | |
| WO2005044192A2 (en) | Triazole compounds and uses related thereto | |
| CN109384729A (zh) | 针对心脏病症的嘧啶二酮化合物 | |
| EA010583B1 (ru) | Производные азетидинкарбоксамида и их применение при лечении нарушений, опосредованных св1 рецепторами | |
| TW201121544A (en) | Novel phenol derivative | |
| EP1932832A1 (en) | Triarylcarboxylic acid derivative | |
| JP2008516902A5 (enExample) | ||
| RU2001120723A (ru) | Производные имидазола и их медицинское применение | |
| JP5781093B2 (ja) | 新たな置換イソキノリン誘導体 | |
| WO2010076034A1 (en) | Toluidine sulfonamides and their use as-inhibitors | |
| MX2011007048A (es) | Toluidin sulfonamidas y su uso. | |
| KR20070045272A (ko) | 2-페닐피리딘 유도체 | |
| WO2012038904A1 (fr) | Derives de nicotinamide, leur preparation et leur application en therapeutique | |
| EP2324015B1 (fr) | Derives de thiophene-2-carboxamide, leur preparation et leur application en therapeutique |